Optomed upgrades its outlook for 2021 due to improved market sentiment and very strong start of the year
Optomed Plc Inside Information 8 April 2021 at 19.30, Helsinki
Optomed upgrades its outlook for 2021 due to improved market sentiment and very strong start of the year
Optomed upgrades its outlook for 2021 due to improved market sentiment and very strong growth during the first quarter of the year.
Seppo Kopsala, Optomed CEO, comments:
“Optomed has started the year with very strong growth. Overall, the COVID-19 pandemic has accelerated the transformation of the diagnostic process towards remote monitoring and screening. For example, diabetics are considered to belong to the COVID-19 high risk group, and it is not recommended for them to visit crowded hospitals or eye clinics for their routine annual eye examinations. This has made handheld fundus cameras very attractive for many clinics and screening operators since they need new diagnostic equipment to treat their patients in a remote way. This transformation seems to be moving eye screening more towards primary care clinics, especially in the US market. The visibility to H2 remains low due to the pandemic, but currently it seems like the ongoing transformation of the fundus camera market towards portable cameras and remote screenings using telemedicine and AI grading is accelerating our growth in 2021.”
The updated outlook for 2021:
Optomed expects its full year 2021 revenue to grow strongly compared to 2020.
The previous outlook for 2021 (announced 18 February 2021):
Optomed expects its full year 2021 revenue to grow compared to 2020.
Optomed will publish the Interim Report for January-March 2021 on 6 May 2021.
Optomed Plc
Further enquiries
Seppo Kopsala, CEO, Optomed Plc, seppo.kopsala@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of over 50 international patents protecting the technology.